Predictive Drug Discovery: How AI Is Transforming Biomedical Innovation
Pharma’s leading innovators are converging on a shared transformation: AI is shifting drug discovery from slow, experimental search to fast, predictive design. Across AstraZeneca, Bristol Myers Squibb, and Merck, a common blueprint is emerging, one built on graph neural networks, generative models, and enterprise‑wide data integration. These approaches are accelerating molecular invention, improving clinical decision‑making, and reshaping how R&D teams operate. The companies that embrace this predictive, data‑centric model will define the next decade of biomedical innovation.